RICHMOND, Va.--(BUSINESS WIRE)--Altria Group, Inc. (NYSE: MO) and its operating company NJOY today respond to the U.S. International Trade Commission (ITC) Administrative Law Judge’s (ALJ) initial determination regarding the patent infringement complaint JUUL Labs, Inc. (JUUL) filed against NJOY.
Last week, the ALJ provided notice of her initial determination supporting JUUL’s allegations in its complaint and recommending an exclusion order that would prohibit the importation of NJOY ACE (ACE) into the United States.
Altria and NJOY respectfully disagree with the ALJ’s initial determination, and NJOY looks forward to presenting its position to the full ITC, which is expected to issue a final decision by December 23, 2024.
In August 2023, NJOY filed a similar, independent patent infringement complaint against JUUL with the ITC seeking a ban on the importation and sale of JUUL products in the United States. A hearing before the ALJ was held in June 2024, and an initial determination is expected in late September. A positive outcome in this case would not preclude an exclusion order against ACE from taking effect.
We continue to work to bring this issue to resolution. The parties have engaged with a mediator to attempt to negotiate a resolution of these disputes. In addition, NJOY recently filed Substantial Equivalence (SE) Exemption requests with the FDA to allow NJOY to market an already-developed ACE product with minor modifications that we believe avoid three of the four JUUL patent claims at issue in the case.
ACE is the first pod-based e-vapor product and the only pod-based menthol e-vapor product authorized by the FDA as appropriate for the protection of public health. An exclusion order banning the importation of ACE would severely limit FDA-authorized choices for adults and undermine public health.
Altria’s Profile
We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. Our Vision is to responsibly lead the transition of adult smokers to a smoke-free future (Vision). We are Moving Beyond Smoking™, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices - believing it is a substantial opportunity for adult tobacco consumers, our businesses and society.
Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S. cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches, and NJOY, LLC (NJOY), an e-vapor manufacturer with a commercialized product portfolio fully covered by marketing granted orders from the U.S. Food and Drug Administration (FDA).
Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products.
Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world’s largest brewer, and Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company.
The brand portfolios of our operating companies include Marlboro®, Black & Mild®, Copenhagen®, Skoal®, on!® and NJOY®. Trademarks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.
Learn more about Altria at www.altria.com and follow us on X (formerly known as Twitter), Facebook and LinkedIn.
Forward-Looking and Cautionary Statements
This release contains certain forward-looking statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to the status of currently pending litigation and regulatory filings, which are inherently subject to risks and uncertainties, and we cannot predict the timing or outcome of any litigation or regulatory filing. Factors that could cause actual results to differ materially from those contained in, or implied by, the forward-looking statements included in this release include uncertainty and delays with respect to pending or future litigation proceedings and regulatory review timelines, and unfavorable outcomes with respect to such litigation proceedings or regulatory reviews, among others. Other risk factors are detailed from time to time in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2023. These forward-looking statements speak only as of the date of this release. We assume no obligation to provide any revisions to, or update, any projections and forward-looking statements contained in, or implied by, this release.
